Sucampo/Takeda’s Amitiza Gains IBS-C Indication
Approval expands the target population for lubiprostone by about 20 million patients, Sucampo commercial head tells “The Pink Sheet” DAILY.
Approval expands the target population for lubiprostone by about 20 million patients, Sucampo commercial head tells “The Pink Sheet” DAILY.